Sassone Biagio, Bertagnin Enrico, Virzì Santo, Simeti Giuseppe, Tolomeo Paolo
Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Cardiothoracic Vascular Department, Division of Provincial Cardiology, Santissima Annunziata Hospital and Delta Hospital, Azienda Unità Sanitaria Locale di Ferrara, 44042 Ferrara, Italy.
Diagnostics (Basel). 2023 Oct 21;13(20):3274. doi: 10.3390/diagnostics13203274.
Although ultrasound-guided axillary vein access (USGAVA) has proven to be a highly effective and safe method for cardiac electronic implantable device (CIED) lead placement, the collapsibility of the axillary vein (AV) during tidal breathing can lead to narrowing or complete collapse, posing a challenge for successful vein puncture and cannulation. We investigated the potential of the Valsalva maneuver (Vm) as a facilitating technique for USGAVA in this context. Out of 148 patients undergoing CIED implantation via USGAVA, 41 were asked to perform the Vm, because they were considered unsuitable for venipuncture due to a narrower AV diameter, as assessed by ultrasound (2.7 ± 1.7 mm vs. 9.1 ± 3.3 mm, < 0.0001). Among them, 37 patients were able to perform the Vm correctly. Overall, the Vm resulted in an average increase in the AV diameter of 4.9 ± 3.4 mm ( < 0.001). USGAVA performed during the Vm was successful in 30 patients (81%), and no Vm-related complications were observed during the 30-day follow-up. In patients with unsuccessful USGAVA, the Vm resulted in a notably smaller increase in AV diameter (0.5 ± 0.3 mm vs. 6.0 ± 2.8 mm, < 0.0001) compared to patients who achieved successful USGAVA, while performing the Vm. Therefore, the Vm is a feasible maneuver to enhance AV diameter and the success rate of USGAVA in most patients undergoing CIED implantation while maintaining safety.
尽管超声引导下腋静脉穿刺置管术(USGAVA)已被证明是心脏电子植入式设备(CIED)导线置入的一种高效且安全的方法,但腋静脉(AV)在潮式呼吸期间的可塌陷性可导致其狭窄或完全塌陷,这给成功的静脉穿刺和置管带来了挑战。在此背景下,我们研究了瓦尔萨尔瓦动作(Vm)作为辅助USGAVA技术的潜力。在148例通过USGAVA进行CIED植入的患者中,41例被要求进行Vm,因为经超声评估,他们因AV直径较窄而被认为不适合静脉穿刺(2.7±1.7mm vs. 9.1±3.3mm,<0.0001)。其中,37例患者能够正确进行Vm。总体而言,Vm使AV直径平均增加了4.9±3.4mm(<0.001)。在Vm期间进行的USGAVA在30例患者中成功(81%),并且在30天随访期间未观察到与Vm相关的并发症。在USGAVA未成功的患者中,与USGAVA成功的患者相比,在进行Vm时,Vm使AV直径的增加明显更小(0.5±0.3mm vs. 6.0±2.8mm,<0.0001)。因此,Vm是一种可行的操作,可在大多数接受CIED植入的患者中增加AV直径和USGAVA的成功率,同时保持安全性。